The lymph system is critical for proper immune function, and inflammation can cause its vessels to close, leading to a number of diseases. Ropirio Therapeutics, Inc., a new Wyss startup, launched to commercialize the first drug that specifically targets and reopens lymphatic vessels. Read more in this story from the Boston Business Journal. #Startup #Entrepreneurship #Therapeutics https://lnkd.in/exTcWgFk
关于我们
At the Wyss Institute, we leverage recent insights into how Nature builds, controls and manufactures to develop new engineering innovations - a new field of research we call Biologically Inspired Engineering. Our scientists, engineers and clinicians, who come from Harvard's Schools of Medicine, Engineering, Arts & Sciences, Design, and Education as well as 12 collaborating academic institutions and hospitals, work alongside staff with industrial experience in product development to engineer transformative solutions to some of the world’s greatest problems. By emulating biological principles of self assembly, organization and regulation, we are developing disruptive technology solutions for healthcare, energy, architecture, robotics, and manufacturing, which are translated into commercial products and therapies through formation of new startups and corporate alliances.
- 网站
-
https://wyss.harvard.edu
Wyss Institute at Harvard University的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- Boston，MA
- 类型
- 非营利机构
- 领域
- Robotics、Bioengineering、Microfluidics、Medicine、Materials Science、Medical Devices、Synthetic Biology、Cell biology、Tissue engineering、Cancer research、Molecular engineering、Organ Engineering、Genome Editing、Molecular Robotics和Immunomaterials
地点
-
主要
获取路线
201 Brookline Ave.
US，MA，Boston，02215
Wyss Institute at Harvard University员工
-
Gangadhar Jogikalmath
Co-Founder Return To Vendor (RTV)
-
Ayis Antoniou
Entrepreneur/mentor/experienced, impactful, innovative leader/strategic advisor looking to connect with early-stage companies in bio-tech
-
James Gorman, M.D., Ph.D.
-
Samir Mitragotri
Professor @ Harvard University | Hiller Professor of Bioengineering | Hansjorg Wyss Professor of Biologically Inspired Engineering | Wyss Institute
动态
-
This story from The Scientist explores how various researchers, including Wyss postdoc?Elizabeth Hann, are exploring how unicellular aquatic organisms could help humanity exist more sustainably. #Sustainability #Microorganisms #SyntheticBiology https://lnkd.in/eV86dvyc
Better Living Through Algae Biotechnology
the-scientist.com
-
Immune-modulating biomaterial technology developed in David Mooney’s group has been licensed to the Wyss startup Attivare Therapeutics, which will first use it to develop new types of immunotherapies for patients with solid tumors and heme malignancies who don’t respond to existing immunotherapies yet. #Immunotherapy #Startups #CancerTreatment https://lnkd.in/gf8zjRJM
-
-
Today we're highlighting Visiting Researcher Carmen Escobedo-Lucea who comes from Teruel, Spain. She explains that she deeply values incorporating traditions from her culture into her daily life. #HispanicHeritageMonth
-
-
Congratulations to Wyss Lumineer Jocelyn (Josie) Kishi, PhD on being named one of MIT Technology Review's 35 Innovators Under 35! Josie left the Wyss with startup Digital Biology, Inc., a precision measurement platform to streamline design of next-generation?therapies. #Biotech #Startups https://lnkd.in/eD34tHma
Josie Kishi
technologyreview.com
-
It's #InternationalPodcastDay! We want to give a shoutout to one of our favorites, Innovate and Elevate. In each episode, host Sharon Kedar, CFA speaks to doctors, scientists, or innovators about cutting-edge discoveries, many related to the grand challenge of women's health. Sharon is also Co-Founder and Partner at Northpond Ventures, a collaborator of the Wyss. What's your favorite podcast that's shining a light on an important topic? https://lnkd.in/eQ_ZXTKp #WomensHealth #Podcast
Innovate and Elevate Podcast
innovateandelevatepodcast.com
-
Researchers working on the Wyss’ Biostasis project have demonstrated that a non-addictive pain relief drug could be used to preserve cells and organs quickly and safely for transplantation, removing the need for static cold storage. The drug compound, named SNC80, can rapidly and reversibly slow biochemical and metabolic activities while preserving cell and tissue viability, which, in the future, could help ensure donor organs can be preserved safely for longer ahead of transplantation and slow the detrimental effects of tissue and organ trauma across a wide range of health emergencies. Megan Sperry #OrganDonorShortage #Therapeutics https://lnkd.in/gBp76sTK
“Suspended animation” drug could aid organ transplantation and survival from traumatic injury
https://wyss.harvard.edu
-
MyoExo is a wearable sensing system to improve diagnosis, and enable improved monitoring of treatments and therapeutic interventions for neurological disorders like Parkinson's disease. #BrainHealth #ParkinsonsDisease #Sensors https://lnkd.in/gdPce5Vj
MyoExo: Wearable Muscle-Centric Sensors for Improved Assessment of Neurological Disorders
https://wyss.harvard.edu
-
Scientists at the Wyss have created an approach to creating living tissue implants from a patient’s own cells for breast reconstruction. This technology, called ReConstruct, has fewer health risks than the current methods. #WomensHealth #CancerSurvivors https://lnkd.in/e_Q9d_wH
ReConstruct: Vascularized tissue for breast reconstruction and augmentation
https://wyss.harvard.edu
-
Congratulations, Phare Bio on receiving this Advanced Research Projects Agency for Health (ARPA-H) grant to enhance a generative artificial intelligence (AI) discovery platform and produce novel classes of antibiotics. We are excited to collaborate with you on this important effort as mounting concern around the antimicrobial resistance crisis. There is an urgent need for new antibiotics that have the potential to save millions of lives.
Today marks a transformational milestone for Phare Bio. We're thrilled to share that we, along with the Collins Lab at Massachusetts Institute of Technology and Harvard University's Wyss Institute, have been awarded up to $27 million from the Advanced Research Projects Agency for Health (ARPA-H)! An agency within the Department of Health and Human Services, ARPA-H funds transformative research to drive biomedical breakthroughs. Thank you, ARPA-H, for this incredible opportunity to bring unprecedented innovation to antimicrobial discovery and rebuild the antibiotic pipeline. ? Funding for the TARGET (Transforming Antibiotic R&D with Generative AI to stop Emerging Threats) Project enables Phare to further optimize our generative AI discovery platform with unparalleled translational precision and design novel antibiotics of critical need. The award also allows us to share our expertly curated machine learning data in an open-access database, thereby galvanizing the next generation of antibiotic researchers and discovery worldwide. From Phare Bio: “The AMR crisis is accelerating, but with this collaboration with ARPA-H, another door is opening. These funds allow Phare Bio to add unprecedented clinical precision to our generative AI discovery platform and develop the novel and specific antibiotics that patients and physicians so vitally need."?- Akhila Kosaraju, MD, CEO/President, Phare Bio “This funding allows us to advance this critical work a step further towards a bespoke, active-learning AI-based platform. Such a tailored AI platform that can target specific clinical needs has yet to be developed across drug discovery, let alone for antibiotics.” - Jim Collins, Ph.D., Co-Founder, Phare Bio From ARPA-H:?“The TARGET project has set the ambitious goal of closing the global gap in discovering novel antibiotics. Generative AI-driven antibiotic drug discovery would revolutionize and revitalize the field to fight superbugs. With TARGET, we aim to discover and generate a set of next-generation antibiotics that can reach the market in time to tackle the antibiotic-resistant pathogens.” - Paul Sheehan, Ph.D., Program Manager, ARPA-H ? Read more about the award and the transformative TARGET Project here: https://bit.ly/3XVN7v8 #AI #Antibiotics #ARPAH #AIforGood #AMR #Innovation